The National Institute for Health and Care Excellence (NICE) has published its Final Appraisal Document for MSD’s letermovir [ID1153] which is subject to appeal, with final guidance expected to be published 31st July 2019.
Letermovir is recommended, within its marketing authorisation, as an option for preventing cytomegalovirus (CMV) reactivation and disease after an allogeneic haematopoietic stem cell transplant (HSCT) in adults who are seropositive for CMV.
Letermovir is recommended as an option for suitable patients only if MSD provides it according to the commercial arrangement reached with NICE.
HSCT can be a life-saving treatment for a range of different diseases including certain cancers such as leukaemia and lymphoma. However, a typical HSCT regimen can weaken the immune system, allowing for the reactivation of CMV in infected individuals.
Approximately 50-80% of adults in the UK are thought to be infected with CMV – a common member of the herpes family of viruses – and, once infected, it often persists in the body in an inactive or latent state, typically causing no symptoms.